Immodin	B:C1254351
and	O
its	O
immune	O
system	I:C0020962
supportive	O
role	O
in	O
paclitaxel	O
therapy	O
of	O
4T1	O
mouse	I:C2986594
breast	O
cancer	I:C0678222
.	O

Immodin	O
and	O
its	O
immune	B:C0020962
system	I:C0020962
supportive	O
role	O
in	O
paclitaxel	O
therapy	O
of	O
4T1	O
mouse	I:C2986594
breast	O
cancer	I:C0678222
.	O

Immodin	O
and	O
its	O
immune	O
system	I:C0020962
supportive	O
role	O
in	O
paclitaxel	B:C0144576
therapy	O
of	O
4T1	O
mouse	I:C2986594
breast	O
cancer	I:C0678222
.	O

Immodin	O
and	O
its	O
immune	O
system	I:C0020962
supportive	O
role	O
in	O
paclitaxel	O
therapy	B:C0087111
of	O
4T1	O
mouse	I:C2986594
breast	O
cancer	I:C0678222
.	O

Immodin	O
and	O
its	O
immune	O
system	I:C0020962
supportive	O
role	O
in	O
paclitaxel	O
therapy	O
of	O
4T1	B:C2986594
mouse	I:C2986594
breast	O
cancer	I:C0678222
.	O

Immodin	O
and	O
its	O
immune	O
system	I:C0020962
supportive	O
role	O
in	O
paclitaxel	O
therapy	O
of	O
4T1	O
mouse	I:C2986594
breast	B:C0678222
cancer	I:C0678222
.	O

It	O
is	O
evident	O
that	O
standard	O
chemotherapy	B:C0003392
agents	I:C0003392
may	O
have	O
an	O
impact	O
on	O
both	O
tumor	O
and	O
host	O
immune	O
system	I:C0020962
.	O

It	O
is	O
evident	O
that	O
standard	O
chemotherapy	O
agents	I:C0003392
may	O
have	O
an	O
impact	O
on	O
both	O
tumor	B:C0027651
and	O
host	O
immune	O
system	I:C0020962
.	O

It	O
is	O
evident	O
that	O
standard	O
chemotherapy	O
agents	I:C0003392
may	O
have	O
an	O
impact	O
on	O
both	O
tumor	O
and	O
host	O
immune	B:C0020962
system	I:C0020962
.	O

Paclitaxel	B:C0144576
(	O
Paclitaxel	O
)	O
,	O
a	O
very	O
potent	O
anticancer	O
drug	I:C0003392
from	O
a	O
taxane	O
family	O
,	O
has	O
achieved	O
prominence	O
in	O
clinical	O
oncology	I:C1274034
for	O
its	O
efficacy	O
against	O
a	O
wide	O
range	O
of	O
tumors	O
including	O
breast	O
cancer	I:C0678222
.	O

Paclitaxel	O
(	O
Paclitaxel	B:C0144576
)	O
,	O
a	O
very	O
potent	O
anticancer	O
drug	I:C0003392
from	O
a	O
taxane	O
family	O
,	O
has	O
achieved	O
prominence	O
in	O
clinical	O
oncology	I:C1274034
for	O
its	O
efficacy	O
against	O
a	O
wide	O
range	O
of	O
tumors	O
including	O
breast	O
cancer	I:C0678222
.	O

Paclitaxel	O
(	O
Paclitaxel	O
)	O
,	O
a	O
very	O
potent	O
anticancer	B:C0003392
drug	I:C0003392
from	O
a	O
taxane	O
family	O
,	O
has	O
achieved	O
prominence	O
in	O
clinical	O
oncology	I:C1274034
for	O
its	O
efficacy	O
against	O
a	O
wide	O
range	O
of	O
tumors	O
including	O
breast	O
cancer	I:C0678222
.	O

Paclitaxel	O
(	O
Paclitaxel	O
)	O
,	O
a	O
very	O
potent	O
anticancer	O
drug	I:C0003392
from	O
a	O
taxane	B:C0215136
family	O
,	O
has	O
achieved	O
prominence	O
in	O
clinical	O
oncology	I:C1274034
for	O
its	O
efficacy	O
against	O
a	O
wide	O
range	O
of	O
tumors	O
including	O
breast	O
cancer	I:C0678222
.	O

Paclitaxel	O
(	O
Paclitaxel	O
)	O
,	O
a	O
very	O
potent	O
anticancer	O
drug	I:C0003392
from	O
a	O
taxane	O
family	O
,	O
has	O
achieved	O
prominence	O
in	O
clinical	B:C1274034
oncology	I:C1274034
for	O
its	O
efficacy	O
against	O
a	O
wide	O
range	O
of	O
tumors	O
including	O
breast	O
cancer	I:C0678222
.	O

Paclitaxel	O
(	O
Paclitaxel	O
)	O
,	O
a	O
very	O
potent	O
anticancer	O
drug	I:C0003392
from	O
a	O
taxane	O
family	O
,	O
has	O
achieved	O
prominence	O
in	O
clinical	O
oncology	I:C1274034
for	O
its	O
efficacy	O
against	O
a	O
wide	O
range	O
of	O
tumors	B:C0027651
including	O
breast	O
cancer	I:C0678222
.	O

Paclitaxel	O
(	O
Paclitaxel	O
)	O
,	O
a	O
very	O
potent	O
anticancer	O
drug	I:C0003392
from	O
a	O
taxane	O
family	O
,	O
has	O
achieved	O
prominence	O
in	O
clinical	O
oncology	I:C1274034
for	O
its	O
efficacy	O
against	O
a	O
wide	O
range	O
of	O
tumors	O
including	O
breast	B:C0678222
cancer	I:C0678222
.	O

However	O
,	O
significant	O
toxicity	B:C0600688
,	O
such	O
as	O
myelosuppression	O
,	O
limit	O
the	O
effectiveness	O
of	O
Paclitaxel	O
-	O
based	O
treatment	O
regimens	I:C0040808
.	O

However	O
,	O
significant	O
toxicity	O
,	O
such	O
as	O
myelosuppression	B:C0854467
,	O
limit	O
the	O
effectiveness	O
of	O
Paclitaxel	O
-	O
based	O
treatment	O
regimens	I:C0040808
.	O

However	O
,	O
significant	O
toxicity	O
,	O
such	O
as	O
myelosuppression	O
,	O
limit	O
the	O
effectiveness	O
of	O
Paclitaxel	B:C0144576
-	O
based	O
treatment	O
regimens	I:C0040808
.	O

However	O
,	O
significant	O
toxicity	O
,	O
such	O
as	O
myelosuppression	O
,	O
limit	O
the	O
effectiveness	O
of	O
Paclitaxel	O
-	O
based	O
treatment	B:C0040808
regimens	I:C0040808
.	O

Immodin	B:C1254351
(	O
Immodin	O
)	O
is	O
low	O
molecular	O
dialysate	O
fraction	I:C0011947
of	O
homogenate	O
made	O
from	O
human	O
leukocytes	O
.	O

Immodin	O
(	O
Immodin	B:C1254351
)	O
is	O
low	O
molecular	O
dialysate	O
fraction	I:C0011947
of	O
homogenate	O
made	O
from	O
human	O
leukocytes	O
.	O

Immodin	O
(	O
Immodin	O
)	O
is	O
low	O
molecular	O
dialysate	B:C0011947
fraction	I:C0011947
of	O
homogenate	O
made	O
from	O
human	O
leukocytes	O
.	O

Immodin	O
(	O
Immodin	O
)	O
is	O
low	O
molecular	O
dialysate	O
fraction	I:C0011947
of	O
homogenate	O
made	O
from	O
human	B:C0086418
leukocytes	O
.	O

Immodin	O
(	O
Immodin	O
)	O
is	O
low	O
molecular	O
dialysate	O
fraction	I:C0011947
of	O
homogenate	O
made	O
from	O
human	O
leukocytes	B:C0023516
.	O

Imreg	B:C0063442
1	I:C0063442
and	O
Imreg	O
2	I:C0030956
formed	O
by	O
the	O
dipeptide	O
tyrosine	O
-	I:C0012512
glycine	I:C0012512
and	O
the	O
tripeptide	O
tyrosine	O
-	I:C0030956
glycine	I:C0030956
-	I:C0030956
glycine	I:C0030956
,	O
respectively	O
.	O

Imreg	O
1	I:C0063442
and	O
Imreg	B:C0030956
2	I:C0030956
formed	O
by	O
the	O
dipeptide	O
tyrosine	O
-	I:C0012512
glycine	I:C0012512
and	O
the	O
tripeptide	O
tyrosine	O
-	I:C0030956
glycine	I:C0030956
-	I:C0030956
glycine	I:C0030956
,	O
respectively	O
.	O

Imreg	O
1	I:C0063442
and	O
Imreg	O
2	I:C0030956
formed	O
by	O
the	O
dipeptide	B:C0012512
tyrosine	O
-	I:C0012512
glycine	I:C0012512
and	O
the	O
tripeptide	O
tyrosine	O
-	I:C0030956
glycine	I:C0030956
-	I:C0030956
glycine	I:C0030956
,	O
respectively	O
.	O

Imreg	O
1	I:C0063442
and	O
Imreg	O
2	I:C0030956
formed	O
by	O
the	O
dipeptide	O
tyrosine	B:C0012512
-	I:C0012512
glycine	I:C0012512
and	O
the	O
tripeptide	O
tyrosine	O
-	I:C0030956
glycine	I:C0030956
-	I:C0030956
glycine	I:C0030956
,	O
respectively	O
.	O

Imreg	O
1	I:C0063442
and	O
Imreg	O
2	I:C0030956
formed	O
by	O
the	O
dipeptide	O
tyrosine	O
-	I:C0012512
glycine	I:C0012512
and	O
the	O
tripeptide	B:C0030956
tyrosine	O
-	I:C0030956
glycine	I:C0030956
-	I:C0030956
glycine	I:C0030956
,	O
respectively	O
.	O

Imreg	O
1	I:C0063442
and	O
Imreg	O
2	I:C0030956
formed	O
by	O
the	O
dipeptide	O
tyrosine	O
-	I:C0012512
glycine	I:C0012512
and	O
the	O
tripeptide	O
tyrosine	B:C0030956
-	I:C0030956
glycine	I:C0030956
-	I:C0030956
glycine	I:C0030956
,	O
respectively	O
.	O

The	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
explore	O
immunopharmacological	O
activities	O
of	O
Immodin	O
,	O
using	O
the	O
strongly	O
immunogenic	O
4T1	O
mouse	I:C2986594
breast	O
cancer	I:C0678222
model	O
,	O
and	O
evaluate	O
its	O
effect	O
on	O
the	O
reactivity	O
and	O
the	O
efficiency	O
of	O
Paclitaxel	O
cancer	O
therapy	I:C0920425
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
immunopharmacological	O
activities	O
of	O
Immodin	B:C1254351
,	O
using	O
the	O
strongly	O
immunogenic	O
4T1	O
mouse	I:C2986594
breast	O
cancer	I:C0678222
model	O
,	O
and	O
evaluate	O
its	O
effect	O
on	O
the	O
reactivity	O
and	O
the	O
efficiency	O
of	O
Paclitaxel	O
cancer	O
therapy	I:C0920425
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
immunopharmacological	O
activities	O
of	O
Immodin	O
,	O
using	O
the	O
strongly	O
immunogenic	O
4T1	B:C2986594
mouse	I:C2986594
breast	O
cancer	I:C0678222
model	O
,	O
and	O
evaluate	O
its	O
effect	O
on	O
the	O
reactivity	O
and	O
the	O
efficiency	O
of	O
Paclitaxel	O
cancer	O
therapy	I:C0920425
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
immunopharmacological	O
activities	O
of	O
Immodin	O
,	O
using	O
the	O
strongly	O
immunogenic	O
4T1	O
mouse	I:C2986594
breast	B:C0678222
cancer	I:C0678222
model	O
,	O
and	O
evaluate	O
its	O
effect	O
on	O
the	O
reactivity	O
and	O
the	O
efficiency	O
of	O
Paclitaxel	O
cancer	O
therapy	I:C0920425
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
immunopharmacological	O
activities	O
of	O
Immodin	O
,	O
using	O
the	O
strongly	O
immunogenic	O
4T1	O
mouse	I:C2986594
breast	O
cancer	I:C0678222
model	O
,	O
and	O
evaluate	O
its	O
effect	O
on	O
the	O
reactivity	O
and	O
the	O
efficiency	O
of	O
Paclitaxel	B:C0144576
cancer	O
therapy	I:C0920425
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
immunopharmacological	O
activities	O
of	O
Immodin	O
,	O
using	O
the	O
strongly	O
immunogenic	O
4T1	O
mouse	I:C2986594
breast	O
cancer	I:C0678222
model	O
,	O
and	O
evaluate	O
its	O
effect	O
on	O
the	O
reactivity	O
and	O
the	O
efficiency	O
of	O
Paclitaxel	O
cancer	B:C0920425
therapy	I:C0920425
.	O

The	O
results	O
highlight	O
a	O
potentially	O
beneficial	O
role	O
for	O
Immodin	B:C1254351
in	O
alleviating	O
Paclitaxel	O
-	O
induced	O
toxicity	O
,	O
especially	O
on	O
the	O
nonspecific	O
immunity	O
,	O
during	O
breast	O
cancer	I:C0678222
therapy	O
.	O

The	O
results	O
highlight	O
a	O
potentially	O
beneficial	O
role	O
for	O
Immodin	O
in	O
alleviating	O
Paclitaxel	B:C0144576
-	O
induced	O
toxicity	O
,	O
especially	O
on	O
the	O
nonspecific	O
immunity	O
,	O
during	O
breast	O
cancer	I:C0678222
therapy	O
.	O

The	O
results	O
highlight	O
a	O
potentially	O
beneficial	O
role	O
for	O
Immodin	O
in	O
alleviating	O
Paclitaxel	O
-	O
induced	O
toxicity	B:C0600688
,	O
especially	O
on	O
the	O
nonspecific	O
immunity	O
,	O
during	O
breast	O
cancer	I:C0678222
therapy	O
.	O

The	O
results	O
highlight	O
a	O
potentially	O
beneficial	O
role	O
for	O
Immodin	O
in	O
alleviating	O
Paclitaxel	O
-	O
induced	O
toxicity	O
,	O
especially	O
on	O
the	O
nonspecific	O
immunity	B:C0020964
,	O
during	O
breast	O
cancer	I:C0678222
therapy	O
.	O

The	O
results	O
highlight	O
a	O
potentially	O
beneficial	O
role	O
for	O
Immodin	O
in	O
alleviating	O
Paclitaxel	O
-	O
induced	O
toxicity	O
,	O
especially	O
on	O
the	O
nonspecific	O
immunity	O
,	O
during	O
breast	B:C0678222
cancer	I:C0678222
therapy	O
.	O

The	O
results	O
highlight	O
a	O
potentially	O
beneficial	O
role	O
for	O
Immodin	O
in	O
alleviating	O
Paclitaxel	O
-	O
induced	O
toxicity	O
,	O
especially	O
on	O
the	O
nonspecific	O
immunity	O
,	O
during	O
breast	O
cancer	I:C0678222
therapy	B:C0087111
.	O

Co-treatment	O
exhibited	O
an	O
antitumor	O
effect	O
including	O
reduced	O
tumor	O
growth	O
,	O
prolonged	O
survival	O
of	O
tumor	B:C0027651
bearing	O
mice	O
,	O
increased	O
number	O
of	O
monocytes	O
and	O
lymphocytes	O
in	O
peripheral	O
blood	I:C0229664
.	O

Co-treatment	O
exhibited	O
an	O
antitumor	O
effect	O
including	O
reduced	O
tumor	O
growth	O
,	O
prolonged	O
survival	O
of	O
tumor	O
bearing	O
mice	B:C2986594
,	O
increased	O
number	O
of	O
monocytes	O
and	O
lymphocytes	O
in	O
peripheral	O
blood	I:C0229664
.	O

Co-treatment	O
exhibited	O
an	O
antitumor	O
effect	O
including	O
reduced	O
tumor	O
growth	O
,	O
prolonged	O
survival	O
of	O
tumor	O
bearing	O
mice	O
,	O
increased	O
number	O
of	O
monocytes	B:C0026473
and	O
lymphocytes	O
in	O
peripheral	O
blood	I:C0229664
.	O

Co-treatment	O
exhibited	O
an	O
antitumor	O
effect	O
including	O
reduced	O
tumor	O
growth	O
,	O
prolonged	O
survival	O
of	O
tumor	O
bearing	O
mice	O
,	O
increased	O
number	O
of	O
monocytes	O
and	O
lymphocytes	B:C0024264
in	O
peripheral	O
blood	I:C0229664
.	O

Co-treatment	O
exhibited	O
an	O
antitumor	O
effect	O
including	O
reduced	O
tumor	O
growth	O
,	O
prolonged	O
survival	O
of	O
tumor	O
bearing	O
mice	O
,	O
increased	O
number	O
of	O
monocytes	O
and	O
lymphocytes	O
in	O
peripheral	B:C0229664
blood	I:C0229664
.	O

In	O
spleens	O
,	O
Immodin	B:C1254351
+	O

Paclitaxel	B:C0144576
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	B:C0087111
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	B:C0024264
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	B:C0229659
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	B:C1171362
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	B:C0023395
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	B:C0034805
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	B:C0108747
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	B:C0054951
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	B:C0039194
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	B:C0022688
cells	I:C0022688
and	O
dendritic	O
cells	I:C0011306
.	O

Paclitaxel	O
therapy	O
elevated	O
proportion	O
of	O
whole	O
lymphocytes	O
in	O
the	O
account	O
of	O
myelo	O
-	I:C0229659
monocytic	I:C0229659
cells	I:C0229659
characteristic	O
with	O
low	O
expression	O
of	O
CD11	O
c	I:C0023395
+	I:C0023395
and	O
bearing	O
Fc	O
receptor	I:C0034805
(	O
CD16	O
/	O
32	O
)	O
as	O
well	O
as	O
T	O
-	I:C0039194
lymphocytes	I:C0039194
,	O
NK	O
cells	I:C0022688
and	O
dendritic	B:C0011306
cells	I:C0011306
.	O

Accumulation	B:C4055506
of	O
tumor	O
-	O
associated	O
granulocytes	O
in	O
stroma	O
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	O
/	O
apoptosis	O
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	B:C0027651
-	O
associated	O
granulocytes	O
in	O
stroma	O
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	O
/	O
apoptosis	O
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	O
-	O
associated	O
granulocytes	B:C0018183
in	O
stroma	O
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	O
/	O
apoptosis	O
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	O
-	O
associated	O
granulocytes	O
in	O
stroma	B:C0927195
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	O
/	O
apoptosis	O
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	O
-	O
associated	O
granulocytes	O
in	O
stroma	O
of	O
Paclitaxel	B:C0144576
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	O
/	O
apoptosis	O
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	O
-	O
associated	O
granulocytes	O
in	O
stroma	O
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	B:C0597032
-	O
necrosis	O
/	O
apoptosis	O
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	O
-	O
associated	O
granulocytes	O
in	O
stroma	O
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	B:C0027540
/	O
apoptosis	O
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	O
-	O
associated	O
granulocytes	O
in	O
stroma	O
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	O
/	O
apoptosis	B:C0162638
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	O
-	O
associated	O
granulocytes	O
in	O
stroma	O
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	O
/	O
apoptosis	O
in	O
tumors	B:C0027651
after	O
co-treatment	O
were	O
also	O
recorded	O
.	O

Accumulation	O
of	O
tumor	O
-	O
associated	O
granulocytes	O
in	O
stroma	O
of	O
Paclitaxel	O
-	O
treated	O
group	O
and	O
intensive	O
4T1	O
-	O
necrosis	O
/	O
apoptosis	O
in	O
tumors	O
after	O
co-treatment	O
were	O
also	O
recorded	B:C0034869
.	O

These	O
findings	B:C0243095
suggest	O
the	O
possibility	O
of	O
using	O
Immodin	O
alongside	O
Paclitaxel	O
treatment	O
for	O
maintaining	O
the	O
immune	O
system	I:C0020962
functions	O
and	O
increasing	O
patient	O
survival	O
.	O

These	O
findings	O
suggest	O
the	O
possibility	O
of	O
using	O
Immodin	B:C1254351
alongside	O
Paclitaxel	O
treatment	O
for	O
maintaining	O
the	O
immune	O
system	I:C0020962
functions	O
and	O
increasing	O
patient	O
survival	O
.	O

These	O
findings	O
suggest	O
the	O
possibility	O
of	O
using	O
Immodin	O
alongside	O
Paclitaxel	B:C0144576
treatment	O
for	O
maintaining	O
the	O
immune	O
system	I:C0020962
functions	O
and	O
increasing	O
patient	O
survival	O
.	O

These	O
findings	O
suggest	O
the	O
possibility	O
of	O
using	O
Immodin	O
alongside	O
Paclitaxel	O
treatment	B:C0087111
for	O
maintaining	O
the	O
immune	O
system	I:C0020962
functions	O
and	O
increasing	O
patient	O
survival	O
.	O

These	O
findings	O
suggest	O
the	O
possibility	O
of	O
using	O
Immodin	O
alongside	O
Paclitaxel	O
treatment	O
for	O
maintaining	O
the	O
immune	B:C0020962
system	I:C0020962
functions	O
and	O
increasing	O
patient	O
survival	O
.	O

